The Lancet Infectious Diseases 今日热榜



The Lancet Infectious Diseases The Lancet Infectious Diseases

1.	[Correspondence] Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations	Jingyi Liu, Yuanling Yu, Fanchong Jian, Sijie Yang, Weiliang Song, Peng Wang, Lingling Yu, Fei Shao, Yunlong Cao	
2.	[Correspondence] DoxyPEP: real-life effectiveness in a cohort of men who have sex with men in Milan, Italy	Angelo Roberto Raccagni, Sara Diotallevi, Riccardo Lolatto, Elena Bruzzesi, Gaia Catalano, Ilaria Mainardi, Chiara Maci, Caterina Candela, Camilla Muccini, Antonella Castagna, Silvia Nozza	
3.	[Comment] Overcoming the global tuberculosis crisis with urgent country-level political and financial action	Suvanand Sahu, Lucica Ditiu, Rizwan Ahmed, Adam Zumla, Eleni Aklillu, Urvashi B Singh, Dorothy Yeboah-Manu, Danny Asogun, David S Hui, Alimuddin Zumla	
4.	[Correspondence] Nipah virus research priorities: who sets them and for whom?	Md Zakiul Hassan, Anoop Kumar A S, Abu Faisal Md Pervez, Tahmina Shirin	
5.	[Articles] Expansion of Oropouche virus in non-endemic Brazilian regions: analysis of genomic characterisation and ecological drivers	Tiago Gräf, Edson Delatorre, Caroline do Nascimento Ferreira, Agata Rossi, Hellen Geremias Gatica Santos, Bianca Ribeiro Pizzato, Valdinete Nascimento, Victor Souza, Gustavo Barbosa de Lima, Filipe Zimmer Dezordi, Alexandre Freitas da Silva, Clarice Neuenschwander Lins de Morais, Ighor Arantes, Mariza Hoffmann Machado, Darcita Buerger Rovaris, Mayra Marinho Presibella, Nelson Fernando Quallio Marques, Emanuelle Gemin Pouzato, Jucelia Stadinicki, Rodrigo Ribeiro-Rodrigues, Thiago de Jesus Sousa, Andréa Cony Cavalcanti, Adriana Cardoso Camargo, Keilla Maria Paz e Silva, Mayara Matias de Oliveira Marques da Costa, Fernanda de Bruycker-Nogueira, Camila Zanluca, Ana Maria Bispo de Filippis, Claudia Nunes Duarte dos Santos, Gabriel Luz Wallau, Gonzalo Bello, Felipe Gomes Naveca, OROV Study Group	
6.	[Comment] Probing Oropouche fever ecology beyond the Amazon	Ignacio Postigo-Hidalgo, Jan Felix Drexler	
7.	[Comment] Is ivermectin surviving expectations in residual malaria control?	Karine Mouline, Carlo Costantini	
8.	[Articles] Adjunctive ivermectin mass drug administration for malaria control on the Bijagos Archipelago of Guinea-Bissau (MATAMAL): a quadruple-blinded, cluster-randomised, placebo-controlled trial	Harry Hutchins, Elizabeth Pretorius, John Bradley, Eunice Teixeira da Silva, Hristina Vasileva, Mamadou Ousmane Ndiath, Robert T Jones, Harouna dit Massire Soumare, Haddy Nyang, Aurelia Prom, Sarata Sambou, Fatima Ceesay, Sainey Ceesay, Sophie Moss, David Mabey, Paulo Djata, Jose Ernesto Nante, Cesario Martins, James G Logan, Hannah Slater, Kevin Tetteh, Chris Drakeley, Umberto D'Alessandro, Amabelia Rodrigues, Anna Last	
9.	[Review] Antimicrobial resistance among refugees and asylum seekers: a global systematic review and meta-analysis	Elizabeth D Hermsen, James Amos, Andy Townsend, Thomas Becker, Sally Hargreaves	
10.	[Correspondence] The dangers of medication sharing at private sex parties	Matthew J Mimiaga, Nina T Harawa	
11.	[Newsdesk] Gilead under fire over HIV drug licensing	Ed Holt	
12.	[Correspondence] Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC	Prerna Arora, Christine Happle, Amy Kempf, Inga Nehlmeier, Metodi V Stankov, Alexandra Dopfer-Jablonka, Georg M N Behrens, Stefan Pöhlmann, Markus Hoffmann	
13.	[Personal View] Research and product development for Crimean–Congo haemorrhagic fever: priorities for 2024–30	Amanda E Semper, Janie Olver, Jenny Warner, Ana Cehovin, Petra C Fay, Peter J Hart, Josephine P Golding, Virginia Benassi, Marie-Pierre Preziosi, Khdair Hazbar Razzaq Al-Asadi, Lucille H Blumberg, José de la Fuente, Nazif Elaldi, Tom Fletcher, Pierre B H Formenty, Mohammad Mehdi Gouya, Stephan Günther, Roger Hewson, Bushra Jamil, Gary Kobinger, Gülay Korukluoglu, Laetitia Lempereur, Gustavo Palacios, Anna Papa, Natalia Pshenichnaya, Connie Schmaljohn, Samba O Sow, Hein Sprong, Zati Vatansever, Timothy J G Brooks	
14.	[Articles] A series of patients infected with the emerging tick-borne Yezo virus in China: an active surveillance and genomic analysis	Ming-Zhu Zhang, Cai Bian, Run-Ze Ye, Xiao-Ming Cui, Nan-Nan Yao, Ji-Hu Yang, Yan-Li Chu, Xiao-Ling Su, Ya-Fei Wu, Jin-Ling Ye, Shun-Shuai Liu, Xiao-Yu Shi, Wenqiang Shi, Na Jia, Yu-Guo Chen, Lin Zhao, Yuan-Chun Zheng, Xiao-Min Zheng, Jia-Fu Jiang, Wu-Chun Cao	
15.	[Comment] Endemic area of emerging tick-borne Yezo virus infections discovered in China	Keita Matsuno	
16.	[Corrections] Correction to Lancet Infect Dis 2024; published online October 7. https://doi.org/10.1016/S1473-3099(24)00561-9		
17.	[Articles] Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study	Prasad S Kulkarni, Anand Kawade, Sunil Kohli, Renuka Munshi, Chetna Maliye, Nithya J Gogtay, Ravish H S, Kiranjit Singh, K Vengadakrishnan, Sandeep Kumar Panigrahi, Jyotiranjan Sahoo, Ashish Bavdekar, B S Garg, Abhishek Raut, Jeffrey P Raj, Unnati Saxena, Vijaya L Chaudhari, Rakesh Patil, Epari Venkatarao, Nitu Kumari, Jithin Surendran, Varsha Parulekar, Luc Gagnon, Tania Gensale, Abhijeet Dharmadhikari, Sunil Gairola, Sameer Kale, Sambhaji S Pisal, Rajeev M Dhere, Asha Mallya, Cyrus S Poonawalla, Dhananjay Kapse	
18.	[Comment] A step closer to elimination of meningococcal disease	Michelle Clarke, Helen S Marshall	
19.	[Correspondence] Virological characteristics of the SARS-CoV-2 XEC variant	Yu Kaku, Kaho Okumura, Shusuke Kawakubo, Keiya Uriu, Luo Chen, Yusuke Kosugi, Yoshifumi Uwamino, MST Monira Begum, Sharee Leong, Terumasa Ikeda, Kenji Sadamasu, Hiroyuki Asakura, Mami Nagashima, Kazuhisa Yoshimura, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Jumpei Ito, Kei Sato	
20.	[Grand Round] A case of disseminated autochthonous Cladophialophora bantiana infection in a renal transplant recipient in the UK	Samuel W Mackrill, David C Schramm, Ali Amini, Riina Rautemaa-Richardson, Nicola Jones, Matthew O Brook, Katie Jeffery, Alexander J Mentzer	
21.	[Corrections] Correction to Lancet Infect Dis 2024; published online Oct 10. https://doi.org/10.1016/S1473-3099(24)00507-3		
22.	[Articles] Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	Rebecca E Colman, Marva Seifert, Andres De la Rossa, Sophia B Georghiou, Christine Hoogland, Swapna Uplekar, Sacha Laurent, Camilla Rodrigues, Priti Kambli, Nestani Tukvadze, Nino Maghradze, Shaheed V Omar, Lavania Joseph, Anita Suresh, Timothy C Rodwell	
23.	[Comment] The promise and the reality of targeted next-generation sequencing for drug-resistant tuberculosis detection	Ben J Marais, Xiaomei Zhang, Vitali Sintchenko	
24.	[Newsdesk] Serious threat of antimicrobial resistance in Ukraine	Ed Holt	
25.	[Correspondence] Predictable excess hepatotoxicity in the SimpliciTB trial – Authors’ reply	Muge Cevik, Maria Beumont, Eugene Sun, Derek J Sloan, Stephen H Gillespie	
26.	[Media Watch] How to face a pandemic	Cahal McQuillan	
27.	[Review] Review of the WHO guideline on preventive chemotherapy for public health control of strongyloidiasis	Nathan C Lo, David G Addiss, Dora Buonfrate, Arancha Amor, Melaku Anegagrie, Zeno Bisoffi, Richard S Bradbury, Jennifer Keiser, Stella Kepha, Virak Khieu, Alejandro Krolewiecki, Jean B Mbonigaba, Jose Muñoz, Francisca Mutapi, Valdemiro Novela, Susana Vaz Nery, Luc E Coffeng, Sake J de Vlas, Jessica Bartoszko, Lorenzo Moja, Denise Mupfasoni, Antonio Montresor	
28.	[Correspondence] Predictable excess hepatotoxicity in the SimpliciTB trial	William Burman, C Robert Horsburgh, James Johnston	
29.	[Articles] Serotype-specific epidemiological patterns of inapparent versus symptomatic primary dengue virus infections: a 17-year cohort study in Nicaragua	Sandra Bos, José Victor Zambrana, Elias Duarte, Aaron L Graber, Julia Huffaker, Carlos Montenegro, Lakshmanane Premkumar, Aubree Gordon, Guillermina Kuan, Angel Balmaseda, Eva Harris	
30.	[Comment] Vaccine and surveillance implications of dengue underdetection	Patrícia Brasil, Jan Felix Drexler	
31.	[Articles] The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial	Dídac Macià, Joseph J Campo, Chenjerai Jairoce, Maximilian Mpina, Hermann Sorgho, David Dosoo, Selidji Todagbe Agnandji, Kwadwo Asamoah Kusi, Luis M Molinos-Albert, Simon Kariuki, Claudia Daubenberger, Benjamin Mordmüller, Gemma Moncunill, Carlota Dobaño	
32.	[Articles] Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial	Yusuke Okada, Yuji Kumagai, Iori Okura, Mako Otsuki, Natsuki Ishida, Yasuhiro Iwama, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Josephine van Boxmeer, Ye Zhang, Igor Smolenov, Judd L Walson	
33.	[Comment] Understanding the immunogenicity of RTS,S in infants	Nirianne Marie Q Palacpac, Toshihiro Horii	
34.	[Comment] Steps towards licensure of self-amplifying RNA vaccines	Maarten F Wilbrink, Sander Herfst, Rory D de Vries	
35.	[Media Watch] COVID-19 in South Asia	Genevieve Pascal	
36.	[Media Watch] Local communities	Henrietta Dunsmuir	
37.	[Media Watch] Vaccine hesitancy on stage	Talha Burki	
38.	[Corrections] Correction to Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7		
39.	[Corrections] Correction to Lancet Infect Dis 2024; published online Sept 27. https://doi.org.10.1016/S1473-3099(24)00618-2		
40.	[Comment] Zoonotic chlamydial infections: what's new?	Nicole Borel	
41.	[Articles] Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	Stijn Raven, Marloes Heijne, Jeroen Koomen, Gert Doornenbal, Miriam Maas, Pieter Jacobs, Ingrid Keur, Frederika Dijkstra, Daphne Reukers, Mark Platenburg, Stephan P Verweij, Hans-Jurgen Mager, Joan Totté, Saara Vainio, Maarten Bongaerts, Edou Heddema	
42.	[Articles] Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	Gabriel C Scachetti, Julia Forato, Ingra M Claro, Xinyi Hua, Bárbara B Salgado, Aline Vieira, Camila L Simeoni, Aguyda R C Barbosa, Italo L Rosa, Gabriela F de Souza, Luana C N Fernandes, Ana Carla H de Sena, Stephanne C Oliveira, Carolina M L Singh, Shirlene T S de Lima, Ronaldo de Jesus, Mariana A Costa, Rodrigo B Kato, Josilene F Rocha, Leandro C Santos, Janete T Rodrigues, Marielton P Cunha, Ester C Sabino, Nuno R Faria, Scott C Weaver, Camila M Romano, Pritesh Lalwani, José Luiz Proenca-Modena, William M de Souza	
43.	[Articles] Newborns with microcephaly in Brazil and potential vertical transmission of Oropouche virus: a case series	Fernanda Eduarda das Neves Martins, Jannifer Oliveira Chiang, Bruno Tardelli Diniz Nunes, Bethania de Freitas Rodrigues Ribeiro, Lívia Carício Martins, Lívia Medeiros Neves Casseb, Daniele Freitas Henriques, Consuelo Silva de Oliveira, Ethel Leonor Noia Maciel, Rafael da Silva Azevedo, Layna de Cássia Campos Cravo, André Rodrigues Façanha Barreto, André Luiz Santos Pessoa, Arnaldo Jorge Martins Filho, Jorge Rodrigues de Sousa, Lavinia Schuler-Faccini, Juarez Antônio Simões Quaresma, Pedro Fernando da Costa Vasconcelos, Raimunda do Socorro da Silva Azevedo	
44.	[Comment] Oropouche virus and potential birth defects	Karin Nielsen-Saines, Patricia Brasil	
45.	[Comment] Re-emergence of Oropouche virus in Brazil and Latin America	Alfonso J Rodriguez-Morales, Jan Felix Drexler	
46.	[Comment] Molecular surveillance in the nirsevimab era: lessons from respiratory syncytial virus breakthrough infections	Narmeen Mallah, Federico Martinón-Torres	
47.	[Articles] Clinical profile analysis of SARS-CoV-2 community infections during periods with omicron BA.2, BA.4/5, and XBB dominance in Hong Kong: a prospective cohort study	Yawei Wang, Hau Chi So, Nicole Ngai Yung Tsang, Siu Kan Kwok, Benjamin J Cowling, Gabriel M Leung, Dennis Kai Ming Ip	
48.	[Comment] Evolving COVID-19 symptoms and the ongoing course of research	Sho Nakakubo	
49.	[Articles] Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study	Slim Fourati, Alawiya Reslan, Jérome Bourret, Jean-Sébastien Casalegno, Yannis Rahou, Lionel Chollet, Sylvie Pillet, Pauline Tremeaux, Nefert Candace Dossou, Elyanne Gault, Maud Salmona, Berthe-Marie Imbert-Marcille, Audrey Mirand, Sylvie Larrat, Alice Moisan, Stéphane Marot, Aurélie Schnuriger, Nicolas Veyrenche, Ilka Engelmann, Lynda Handala, Amandine Henry, Valentin Stephan, Ségolène Brichler, Véronique Avettand-Fenoel, Nael Zemali, Caroline Lefeuvre, Charlotte Pronier, Luc Deroche, Marie-Christine Jaffar-Bandjee, Lina Mouna, Catherine Francois, Alexandre Regueme, Cédric Hartard, Sylvie Rogez, Floriane Gallais, Arnaud Ly, Christophe Rodriguez, Georges Dos Santos, Etienne Simon-Loriere, Olivier Schwartz, Julian Buchrieser, Jean-MiIchel Pawlotsky, Frédéric Lemoine, Etienne Audureau, Marie-Anne Rameix-Welti, POLYRES investigators	
50.	[Articles] Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation	Ahmed Babiker, Sarah Warner, Xiaobai Li, Emad A Chishti, Eltaib Saad, Bruce J Swihart, John P Dekker, Morgan Walker, Alexander Lawandi, Sameer S Kadri	
51.	[Comment] Time to turn off the toxins: adjuvant suppression of group A streptococcus	Michael Marks, Shiranee Sriskandan	
52.	[Media Watch] Two pandemics, a shared lesson	Emma Starbuck	
53.	[Corrections] Correction to Lancet Infect Dis 2021; 21: 823–33		
54.	[Comment] Revisiting MERS-CoV vaccination in the SARS-CoV-2 era	Sarah A Batawi, Basem M Alraddadi	
55.	[Articles] Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial	Matthijs P Raadsen, Christine Dahlke, Anahita Fathi, Svenja Hardtke, Michael Klüver, Verena Krähling, Gesche K Gerresheim, Leonie Mayer, Anna Z Mykytyn, Leonie M Weskamm, Tamara Zoran, Eric C M van Gorp, Gerd Sutter, Stephan Becker, Bart L Haagmans, Marylyn M Addo, MVA-MERS-S_DF-1 Study group	
56.	[Articles] Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial	Yehuda Carmeli, José Miguel Cisneros, Mical Paul, George L Daikos, Minggui Wang, Julian Torre-Cisneros, George Singer, Ivan Titov, Illia Gumenchuk, Yongjie Zhao, Rosa-María Jiménez-Rodríguez, Lu Liang, Gang Chen, Oleksandr Pyptiuk, Firdevs Aksoy, Halley Rogers, Michele Wible, Francis F Arhin, Alison Luckey, Joanne L Leaney, Rienk Pypstra, Joseph W Chow, COMBACTE-CARE consortium REVISIT study group	
57.	[Comment] REVISITing treatment of metallo-β-lactamases	Emily L Heil, Erin K McCreary	
58.	[Review] New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine	Andreas K Lindner, Veerle Lejon, Michael P Barrett, Lucille Blumberg, Salome A Bukachi, Rebecca J Chancey, Andrew Edielu, Lucas Matemba, Tihitina Mesha, Victor Mwanakasale, Christopher Pasi, Tapunda Phiri, Jorge Seixas, Elie A Akl, Katrin Probyn, Gemma Villanueva, Pere P Simarro, Augustin Kadima Ebeja, Jose R Franco, Gerardo Priotto	
59.	[Correspondence] 12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Pad Chivukula, Ye Zhang, Judd L Walson	
60.	[Media Watch] Fail to prepare, prepare to fail	Jessica Pope	
61.	[Comment] Heading in the direction of ending human deaths from dog-mediated rabies	Maria Cristina Schneider, Sofia Sciancalepore	
62.	[Articles] Estimates of the burden of human rabies deaths and animal bites in India, 2022–23: a community-based cross-sectional survey and probability decision-tree modelling study	Jeromie Wesley Vivian Thangaraj, Navaneeth S Krishna, Shanmugasundaram Devika, Suganya Egambaram, Sudha Rani Dhanapal, Siraj Ahmed Khan, Ashok Kumar Srivastava, Ayush Mishra, Basavaraj Shrinivasa, Devendra Gour, Major Madhukar, Nirmal Verma, Parul Sharma, Ravinder Kumar Soni, Sabarinathan Ramasamy, Sreelakshmi Mohandas, Subrata Baidya, Tanveer Rehman, Vijay V Yeldandi, Akashdeep Singh, Aswathy Sreedevi, Babasaheb V Tandale, Debjani Ram Purakayastha, Mahendra M Reddy, Manju Toppo, Nitinkumar Valjibhai Solanki, Pramit Ghosh, Prashant Jaiswal, Shaili Vyas, Shampa Das, Subrata Kumar Palo, Venela Prasanth, Amanda G A Rozario, Chokkalingam Durairajan, Anitha Delli, Aruna Sasi, Chandhini Pandiyan, Doddabale Hanumanthaiah Ashwathnarayana, Sam Joy, Srikrishna Isloor, Mysore Kalappa Sudarshan, Manju Rahi, Manoj V Murhekar, Human Rabies Study Collaborators	
63.	[Correspondence] Preparing for the rapid research response to the possible vertical transmission of Oropouche virus: lessons from a decade of congenital Zika research	Elizabeth B Brickley, Demócrito de Barros Miranda-Filho, Ricardo Arraes de Alencar Ximenes, MERG, ZBC-Consortium, and LIFE Zika Study members	
64.	[Personal View] Advancing the chemotherapy of tuberculous meningitis: a consensus view	Sean Wasserman, Joseph Donovan, Evelyne Kestelyn, James A Watson, Robert E Aarnoutse, James R Barnacle, David R Boulware, Felicia C Chow, Fiona V Cresswell, Angharad G Davis, Kelly E Dooley, Anthony A Figaji, Diana M Gibb, Julie Huynh, Darma Imran, Suzaan Marais, David B Meya, Usha K Misra, Manish Modi, Mihaja Raberahona, Ahmad Rizal Ganiem, Ursula K Rohlwink, Rovina Ruslami, James A Seddon, Keira H Skolimowska, Regan S Solomons, Cari J Stek, Nguyen Thuy Thuong Thuong, Reinout van Crevel, Claire Whitaker, Guy E Thwaites, Robert J Wilkinson	
65.	[Articles] Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial	Amparo L Figueroa, Dania Torres, Celia Reyes-Acuna, Paul Matherne, Anne Yeakey, Weiping Deng, Wenqin Xu, Yelena Sigal, Greer Chambers, Michelle Olsen, Bethany Girard, Jacqueline M Miller, Rituparna Das, Frances Priddy	
66.	[Comment] COVID-19 immunisation strategies for adolescents	Wei-Xiao Wang, Feng-Cai Zhu	
67.	[Review] The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access	Jonne Terstappen, Sarah F Hak, Anant Bhan, Debby Bogaert, Louis J Bont, Ursula J Buchholz, Andrew D Clark, Cheryl Cohen, Ron Dagan, Daniel R Feikin, Barney S Graham, Anuradha Gupta, Pradeep Haldar, Rose Jalang'o, Ruth A Karron, Leyla Kragten, You Li, Yvette N Löwensteyn, Patrick K Munywoki, Rosemary Njogu, Ab Osterhaus, Andrew J Pollard, Luiza Reali Nazario, Charles Sande, Ashish R Satav, Padmini Srikantiah, Renato T Stein, Naveen Thacker, Rachael Thomas, Marta Tufet Bayona, Natalie I Mazur	
68.	[Review] Optimising vaccine immunogenicity in ageing populations: key strategies	Guangzhen Jiang, Yushu Zou, Dongyu Zhao, Jingyou Yu	
69.	[Personal View] A pox on all our houses: a missing component in the global mpox response is equity	Eddy Jonas, Nesar Hamraz, Nathalie Marcadieu, Daphnee Salomon, Deogratias Niyizonkiza, Jennifer Furin, Jacklin Saint Fleur	
70.	[Comment] Difficulties in diagnosing tuberculosis infection in childhood	Anna Starshinova	
71.	[Articles] Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study	Laura Olbrich, Zoe Franckling-Smith, Leyla Larsson, Issa Sabi, Nyanda Elias Ntinginya, Celso Khosa, Denise Banze, Marriott Nliwasa, Elizabeth Lucy Corbett, Robina Semphere, Valsan Philip Verghese, Joy Sarojini Michael, Marilyn Mary Ninan, Elmar Saathoff, Timothy Daniel McHugh, Alia Razid, Stephen Michael Graham, Rinn Song, Pamela Nabeta, Andre Trollip, Mark Patrick Nicol, Michael Hoelscher, Christof Geldmacher, Norbert Heinrich, Heather Joy Zar, RaPaed-AIDA-TB consortium	
72.	[Articles] Mosquito-disseminated pyriproxyfen for mosquito-borne disease control in Belo Horizonte, Brazil: a pragmatic, before–after control–intervention paired-series trial	Fernando Abad-Franch, José Joaquín Carvajal-Cortés, Ana Carolina Lemos Rabelo, Eduardo Viana Vieira Gusmão, Samylla Suany de Souza Soares, Sérgio Luiz Bessa Luz	
73.	[Comment] Quantifying the effect of vector targeted interventions to control dengue	Henrik Salje	
74.	[Articles] Temporary adaptations to sexual behaviour during the mpox outbreak in 23 countries in Europe and the Americas: findings from a retrospective cross-sectional online survey	Mateo Prochazka, Pietro Vinti, Ana Hoxha, Andy Seale, Antons Mozalevskis, Rosamund Lewis, Ruben Mayorga Sagastume, Martha Scherzer, Leilia Dore, Meg Doherty	
75.	[Personal View] Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	Richard Kwizera, Alireza Abdolrasouli, Guillermo Garcia-Effron, David W Denning	
76.	[Comment] Mpox control strategies: using behaviour change to complement, not replace, vaccination	Marc C Shamier, Kai J Jonas	
77.	[Articles] Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study	Timothy W Russell, Hermaleigh Townsley, Joel Hellewell, Joshua Gahir, Marianne Shawe-Taylor, David Greenwood, David Hodgson, Agnieszka Hobbs, Giulia Dowgier, Rebecca Penn, Theo Sanderson, Phoebe Stevenson-Leggett, James Bazire, Ruth Harvey, Ashley S Fowler, Murad Miah, Callie Smith, Mauro Miranda, Philip Bawumia, Harriet V Mears, Lorin Adams, Emine Hatipoglu, Nicola O'Reilly, Scott Warchal, Karen Ambrose, Amy Strange, Gavin Kelly, Svend Kjar, Padmasayee Papineni, Tumena Corrah, Richard Gilson, Vincenzo Libri, George Kassiotis, Steve Gamblin, Nicola S Lewis, Bryan Williams, Charles Swanton, Sonia Gandhi, Rupert Beale, Mary Y Wu, David L V Bauer, Edward J Carr, Emma C Wall, Adam J Kucharski	
78.	[Comment] Kinetics of neutralising antibodies against SARS-CoV-2 variants	Piero Poletti	
79.	[Comment] SARS-CoV-2 antivirals and post-COVID-19 condition	Ziyad Al-Aly	
80.	[Articles] Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021	GBD 2021 Upper Respiratory Infections Otitis Media Collaborators	
81.	[Articles] Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial	Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, Najib M Rahman, Duncan B Richards, Gail Hayward, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Stavros Petrou, Kerenza Hood, Haroon Ahmed, Andrew Carson-Stevens, Jonathan S Nguyen-Van-Tam, Mahendra G Patel, Benjamin R Saville, Nick Francis, Nicholas P B Thomas, Philip Evans, Melissa Dobson, May Ee Png, Mark Lown, Oliver van Hecke, Bhautesh D Jani, Nigel D Hart, Daniel Butler, Lucy Cureton, Meena Patil, Monique Andersson, Maria Coates, Clare Bateman, Jennifer C Davies, Ivy Raymundo-Wood, Andrew Ustianowski, Ly-Mee Yu, F D Richard Hobbs, Paul Little, Christopher C Butler, PANORAMIC Trial Collaborative Group	
82.	[Comment] Burden of upper respiratory infections and otitis media	Tal Marom	
83.	[Comment] Next-generation influenza vaccines based on mRNA technology	Irina Isakova-Sivak, Larisa Rudenko	
84.	[Articles] Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50–75 years: a phase 1/2, open-label, randomised trial	Denise Hsu, Akila Jayaraman, Alicia Pucci, Riya Joshi, Kevin Mancini, Hui Ling Chen, Kindra Koslovsky, Xuezhou Mao, Angela Choi, Carole Henry, Jignesh Vakil, Daniel Stadlbauer, Patricia Jorquera, Guha Asthagiri Arunkumar, Nelia E Sanchez-Crespo, L Tyler Wadsworth, Vellore Bhupathy, Evelyn Du, Andrei Avanesov, Jintanat Ananworanich, Raffael Nachbagauer	
85.	[Articles] The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review	Suzanne M E Kuijpers, David T P Buis, Kirsten A Ziesemer, Reinier M van Hest, Rogier P Schade, Kim C E Sigaloff, Jan M Prins	
86.	[Articles] Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents	Vera Buerger, Sandra Hadl, Martina Schneider, Michaela Schaden, Romana Hochreiter, Annegret Bitzer, Karin Kosulin, Robert Mader, Oliver Zoihsl, Andrea Pfeiffer, Ana Paula Loch, Eolo Morandi, Mauricio Lacerda Nogueira, Carlos Alexandre Antunes de Brito, Julio Croda, Mauro Martins Teixeira, Ivo Castelo-Branco Coelho, Ricardo Gurgel, Allex Jardim da Fonseca, Marcus Vinícius Guimarães de Lacerda, Edson Duarte Moreira, Ana Paula Rocha Veiga, Katrin Dubischar, Nina Wressnigg, Susanne Eder-Lingelbach, Juan Carlos Jaramillo	
87.	[Comment] Shorter antibiotic courses for respiratory tract infections	Javeria Tariq, Ritu Banerjee	
88.	[Comment] First immunogenicity and safety data on live chikungunya vaccine in an endemic area	David O Freedman, Annika Beate Wilder-Smith, Annelies Wilder-Smith	
89.	[Articles] Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial	Flonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, Jennifer D Hamilton, Benjamin A Olenchock, Taylor Brackin, Samit Ganguly, Eduardo Forleo-Neto, Lori Faria, Ingeborg Heirman, Mary Marovich, Julia Hutter, Laura Polakowski, Susan C Irvin, Mazhar Thakur, Andrea T Hooper, Alina Baum, Christopher D Petro, Faisal A Fakih, M Juliana McElrath, Stephen C De Rosa, Kristen W Cohen, LaTonya D Williams, Caleb A Hellman, Ahmad J Odeh, Aloki H Patel, Georgia D Tomaras, Gregory P Geba, Christos A Kyratsous, Bret Musser, George D Yancopoulos, Gary A Herman, Trial Working Group	
90.	[Comment] Weighing up monoclonals and vaccination against COVID-19	David L V Bauer	
91.	[Comment] Assessing the real-world effectiveness of the rVSV-ZEBOV vaccine	Deborah A Williamson, Emma C Thomson	
92.	[Articles] Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study	Sophie Meakin, Justus Nsio, Anton Camacho, Richard Kitenge, Rebecca M Coulborn, Etienne Gignoux, John Johnson, Esther Sterk, Elisabeth Mukamba Musenga, Stephane Hans Bateyi Mustafa, Epicentre-MSF EVD Working Group, Flavio Finger, Steve Ahuka-Mundeke	
93.	[Comment] Preconception immunisation to prevent pregnancy-associated malaria	Stephanie K Yanow, Daniel Ferrer Vinals	
94.	[Articles] Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial	Kayvon Modjarrad, Paul T Scott, Melanie McCauley, Brittany Ober-Shepherd, Erica Sondergaard, Mihret F Amare, Ajay P Parikh, Badryah Omar, Ada-Marie Minutello, Haritha Adhikarla, Yukun Wu, Andrey Rojas P, Valentine Delore, Nathalie Mantel, Meshell N Morrison, Kamila S Kourbanova, Melissa E Martinez, Ivelese Guzman, Melissa E Greenleaf, Janice M Darden, Michael A Koren, Melinda J Hamer, Christine E Lee, Jack N Hutter, Sheila A Peel, Merlin L Robb, Manuel Vangelisti, Emmanuel Feroldi	
95.	[Articles] Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials	Halimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, Djibrilla Issiaka, Aye Diallo, Seydou Traore, Ibrahim H Soumbounou, Santara Gaoussou, Irfan Zaidi, Almahamoudou Mahamar, Oumar Attaher, Michal Fried, Blair J Wylie, Rathy Mohan, Viyada Doan, Justin Y A Doritchamou, Amagana Dolo, Robert D Morrison, Jing Wang, Zonghui Hu, Kelly M Rausch, Amatigue Zeguime, Tooba Murshedkar, Natasha KC, B Kim Lee Sim, Peter F Billingsley, Thomas L Richie, Stephen L Hoffman, Alassane Dicko, Patrick E Duffy, PfSPZ Vaccine Study Team	
96.	[Comment] The promising prospects of a new yellow fever vaccine	Anna H E Roukens, Leo G Visser	
97.	[Articles] Investigating the effect of enhanced cleaning and disinfection of shared medical equipment on health-care-associated infections in Australia (CLEEN): a stepped-wedge, cluster randomised, controlled trial	Katrina Browne, Nicole M White, Philip L Russo, Allen C Cheng, Andrew J Stewardson, Georgia Matterson, Peta E Tehan, Kirsty Graham, Maham Amin, Maria Northcote, Martin Kiernan, Jennie King, David Brain, Brett G Mitchell	
98.	[Articles] Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007–22)	Thi Mui Pham, Yue Zhang, McKenna Nevers, Haojia Li, Karim Khader, Yonatan H Grad, Marc Lipsitch, Matthew Samore	
99.	[Comment] Success of the CLEEN study	Dinah Gould, Nicolas Drey	
100.	[Comment] Antibiotic resistance incidence or proportions: where does the greatest burden lie?	Morgan K Walker, Sameer S Kadri	

更新于 14 分钟前

近期历史最近 100 条记录

2024-11-23	[Correspondence] Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations	Jingyi Liu, Yuanling Yu, Fanchong Jian, Sijie Yang, Weiliang Song, Peng Wang, Lingling Yu, Fei Shao, Yunlong Cao	
2024-11-20	[Correspondence] DoxyPEP: real-life effectiveness in a cohort of men who have sex with men in Milan, Italy	Angelo Roberto Raccagni, Sara Diotallevi, Riccardo Lolatto, Elena Bruzzesi, Gaia Catalano, Ilaria Mainardi, Chiara Maci, Caterina Candela, Camilla Muccini, Antonella Castagna, Silvia Nozza	
2024-11-20	[Comment] Overcoming the global tuberculosis crisis with urgent country-level political and financial action	Suvanand Sahu, Lucica Ditiu, Rizwan Ahmed, Adam Zumla, Eleni Aklillu, Urvashi B Singh, Dorothy Yeboah-Manu, Danny Asogun, David S Hui, Alimuddin Zumla	
2024-11-19	[Correspondence] Nipah virus research priorities: who sets them and for whom?	Md Zakiul Hassan, Anoop Kumar A S, Abu Faisal Md Pervez, Tahmina Shirin	
2024-11-16	[Articles] Expansion of Oropouche virus in non-endemic Brazilian regions: analysis of genomic characterisation and ecological drivers	Tiago Gräf, Edson Delatorre, Caroline do Nascimento Ferreira, Agata Rossi, Hellen Geremias Gatica Santos, Bianca Ribeiro Pizzato, Valdinete Nascimento, Victor Souza, Gustavo Barbosa de Lima, Filipe Zimmer Dezordi, Alexandre Freitas da Silva, Clarice Neuen	
2024-11-16	[Comment] Probing Oropouche fever ecology beyond the Amazon	Ignacio Postigo-Hidalgo, Jan Felix Drexler	
2024-11-15	[Comment] Is ivermectin surviving expectations in residual malaria control?	Karine Mouline, Carlo Costantini	
2024-11-15	[Articles] Adjunctive ivermectin mass drug administration for malaria control on the Bijagos Archipelago of Guinea-Bissau (MATAMAL): a quadruple-blinded, cluster-randomised, placebo-controlled trial	Harry Hutchins, Elizabeth Pretorius, John Bradley, Eunice Teixeira da Silva, Hristina Vasileva, Mamadou Ousmane Ndiath, Robert T Jones, Harouna dit Massire Soumare, Haddy Nyang, Aurelia Prom, Sarata Sambou, Fatima Ceesay, Sainey Ceesay, Sophie Moss, David	
2024-11-09	[Review] Antimicrobial resistance among refugees and asylum seekers: a global systematic review and meta-analysis	Elizabeth D Hermsen, James Amos, Andy Townsend, Thomas Becker, Sally Hargreaves	
2024-11-09	[Correspondence] The dangers of medication sharing at private sex parties	Matthew J Mimiaga, Nina T Harawa	
2024-11-09	[Newsdesk] Gilead under fire over HIV drug licensing	Ed Holt	
2024-11-08	[Personal View] Research and product development for Crimean–Congo haemorrhagic fever: priorities for 2024–30	Amanda E Semper, Janie Olver, Jenny Warner, Ana Cehovin, Petra C Fay, Peter J Hart, Josephine P Golding, Virginia Benassi, Marie-Pierre Preziosi, Khdair Hazbar Razzaq Al-Asadi, Lucille H Blumberg, José de la Fuente, Nazif Elaldi, Tom Fletcher, Pierre B H	
2024-11-08	[Correspondence] Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC	Prerna Arora, Christine Happle, Amy Kempf, Inga Nehlmeier, Metodi V Stankov, Alexandra Dopfer-Jablonka, Georg M N Behrens, Stefan Pöhlmann, Markus Hoffmann	
2024-11-08	[Articles] A series of patients infected with the emerging tick-borne Yezo virus in China: an active surveillance and genomic analysis	Ming-Zhu Zhang, Cai Bian, Run-Ze Ye, Xiao-Ming Cui, Nan-Nan Yao, Ji-Hu Yang, Yan-Li Chu, Xiao-Ling Su, Ya-Fei Wu, Jin-Ling Ye, Shun-Shuai Liu, Xiao-Yu Shi, Wenqiang Shi, Na Jia, Yu-Guo Chen, Lin Zhao, Yuan-Chun Zheng, Xiao-Min Zheng, Jia-Fu Jiang, Wu-Chun	
2024-11-08	[Comment] Endemic area of emerging tick-borne Yezo virus infections discovered in China	Keita Matsuno	
2024-11-07	[Corrections] Correction to Lancet Infect Dis 2024; published online October 7. https://doi.org/10.1016/S1473-3099(24)00561-9		
2024-11-07	[Comment] A step closer to elimination of meningococcal disease	Michelle Clarke, Helen S Marshall	
2024-11-07	[Articles] Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study	Prasad S Kulkarni, Anand Kawade, Sunil Kohli, Renuka Munshi, Chetna Maliye, Nithya J Gogtay, Ravish H S, Kiranjit Singh, K Vengadakrishnan, Sandeep Kumar Panigrahi, Jyotiranjan Sahoo, Ashish Bavdekar, B S Garg, Abhishek Raut, Jeffrey P Raj, Unnati Saxena,	
2024-11-07	[Correspondence] Virological characteristics of the SARS-CoV-2 XEC variant	Yu Kaku, Kaho Okumura, Shusuke Kawakubo, Keiya Uriu, Luo Chen, Yusuke Kosugi, Yoshifumi Uwamino, MST Monira Begum, Sharee Leong, Terumasa Ikeda, Kenji Sadamasu, Hiroyuki Asakura, Mami Nagashima, Kazuhisa Yoshimura, The Genotype to Phenotype Japan (G2P-Jap	
2024-11-06	[Grand Round] A case of disseminated autochthonous Cladophialophora bantiana infection in a renal transplant recipient in the UK	Samuel W Mackrill, David C Schramm, Ali Amini, Riina Rautemaa-Richardson, Nicola Jones, Matthew O Brook, Katie Jeffery, Alexander J Mentzer	
2024-11-05	[Corrections] Correction to Lancet Infect Dis 2024; published online Oct 10. https://doi.org/10.1016/S1473-3099(24)00507-3		
2024-10-30	[Articles] Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	Rebecca E Colman, Marva Seifert, Andres De la Rossa, Sophia B Georghiou, Christine Hoogland, Swapna Uplekar, Sacha Laurent, Camilla Rodrigues, Priti Kambli, Nestani Tukvadze, Nino Maghradze, Shaheed V Omar, Lavania Joseph, Anita Suresh, Timothy C Rodwell	
2024-10-30	[Comment] The promise and the reality of targeted next-generation sequencing for drug-resistant tuberculosis detection	Ben J Marais, Xiaomei Zhang, Vitali Sintchenko	
2024-10-29	[Newsdesk] Serious threat of antimicrobial resistance in Ukraine	Ed Holt	
2024-10-29	[Correspondence] Predictable excess hepatotoxicity in the SimpliciTB trial	William Burman, C Robert Horsburgh, James Johnston	
2024-10-29	[Correspondence] Predictable excess hepatotoxicity in the SimpliciTB trial – Authors’ reply	Muge Cevik, Maria Beumont, Eugene Sun, Derek J Sloan, Stephen H Gillespie	
2024-10-29	[Review] Review of the WHO guideline on preventive chemotherapy for public health control of strongyloidiasis	Nathan C Lo, David G Addiss, Dora Buonfrate, Arancha Amor, Melaku Anegagrie, Zeno Bisoffi, Richard S Bradbury, Jennifer Keiser, Stella Kepha, Virak Khieu, Alejandro Krolewiecki, Jean B Mbonigaba, Jose Muñoz, Francisca Mutapi, Valdemiro Novela, Susana Vaz	
2024-10-29	[Media Watch] How to face a pandemic	Cahal McQuillan	
2024-10-26	[Articles] Serotype-specific epidemiological patterns of inapparent versus symptomatic primary dengue virus infections: a 17-year cohort study in Nicaragua	Sandra Bos, José Victor Zambrana, Elias Duarte, Aaron L Graber, Julia Huffaker, Carlos Montenegro, Lakshmanane Premkumar, Aubree Gordon, Guillermina Kuan, Angel Balmaseda, Eva Harris	
2024-10-26	[Comment] Vaccine and surveillance implications of dengue underdetection	Patrícia Brasil, Jan Felix Drexler	
2024-10-24	[Articles] The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical	Dídac Macià, Joseph J Campo, Chenjerai Jairoce, Maximilian Mpina, Hermann Sorgho, David Dosoo, Selidji Todagbe Agnandji, Kwadwo Asamoah Kusi, Luis M Molinos-Albert, Simon Kariuki, Claudia Daubenberger, Benjamin Mordmüller, Gemma Moncunill, Carlota Dobaño	
2024-10-24	[Articles] Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial	Yusuke Okada, Yuji Kumagai, Iori Okura, Mako Otsuki, Natsuki Ishida, Yasuhiro Iwama, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Josephine van Boxmeer, Ye Zhang, Igor Smolenov, Judd L Walson	
2024-10-24	[Comment] Understanding the immunogenicity of RTS,S in infants	Nirianne Marie Q Palacpac, Toshihiro Horii	
2024-10-24	[Comment] Steps towards licensure of self-amplifying RNA vaccines	Maarten F Wilbrink, Sander Herfst, Rory D de Vries	
2024-10-23	[Media Watch] COVID-19 in South Asia	Genevieve Pascal	
2024-10-23	[Media Watch] Local communities	Henrietta Dunsmuir	
2024-10-23	[Media Watch] Vaccine hesitancy on stage	Talha Burki	
2024-10-19	[Corrections] Correction to Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7		
2024-10-19	[Corrections] Correction to Lancet Infect Dis 2024; published online Sept 27. https://doi.org.10.1016/S1473-3099(24)00618-2		
2024-10-17	[Articles] Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	Stijn Raven, Marloes Heijne, Jeroen Koomen, Gert Doornenbal, Miriam Maas, Pieter Jacobs, Ingrid Keur, Frederika Dijkstra, Daphne Reukers, Mark Platenburg, Stephan P Verweij, Hans-Jurgen Mager, Joan Totté, Saara Vainio, Maarten Bongaerts, Edou Heddema	
2024-10-17	[Comment] Zoonotic chlamydial infections: what's new?	Nicole Borel	
2024-10-16	[Articles] Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	Gabriel C Scachetti, Julia Forato, Ingra M Claro, Xinyi Hua, Bárbara B Salgado, Aline Vieira, Camila L Simeoni, Aguyda R C Barbosa, Italo L Rosa, Gabriela F de Souza, Luana C N Fernandes, Ana Carla H de Sena, Stephanne C Oliveira, Carolina M L Singh, Shir	
2024-10-16	[Articles] Newborns with microcephaly in Brazil and potential vertical transmission of Oropouche virus: a case series	Fernanda Eduarda das Neves Martins, Jannifer Oliveira Chiang, Bruno Tardelli Diniz Nunes, Bethania de Freitas Rodrigues Ribeiro, Lívia Carício Martins, Lívia Medeiros Neves Casseb, Daniele Freitas Henriques, Consuelo Silva de Oliveira, Ethel Leonor Noia M	
2024-10-16	[Comment] Oropouche virus and potential birth defects	Karin Nielsen-Saines, Patricia Brasil	
2024-10-16	[Comment] Re-emergence of Oropouche virus in Brazil and Latin America	Alfonso J Rodriguez-Morales, Jan Felix Drexler	
2024-10-16	[Editorial] The responsibility of publishing early outbreak data	The Lancet Infectious Diseases	
2024-10-15	[Comment] Molecular surveillance in the nirsevimab era: lessons from respiratory syncytial virus breakthrough infections	Narmeen Mallah, Federico Martinón-Torres	
2024-10-15	[Articles] Clinical profile analysis of SARS-CoV-2 community infections during periods with omicron BA.2, BA.4/5, and XBB dominance in Hong Kong: a prospective cohort study	Yawei Wang, Hau Chi So, Nicole Ngai Yung Tsang, Siu Kan Kwok, Benjamin J Cowling, Gabriel M Leung, Dennis Kai Ming Ip	
2024-10-15	[Comment] Evolving COVID-19 symptoms and the ongoing course of research	Sho Nakakubo	
2024-10-15	[Articles] Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study	Slim Fourati, Alawiya Reslan, Jérome Bourret, Jean-Sébastien Casalegno, Yannis Rahou, Lionel Chollet, Sylvie Pillet, Pauline Tremeaux, Nefert Candace Dossou, Elyanne Gault, Maud Salmona, Berthe-Marie Imbert-Marcille, Audrey Mirand, Sylvie Larrat, Alice Mo	
2024-10-11	[Articles] Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation	Ahmed Babiker, Sarah Warner, Xiaobai Li, Emad A Chishti, Eltaib Saad, Bruce J Swihart, John P Dekker, Morgan Walker, Alexander Lawandi, Sameer S Kadri	
2024-10-11	[Comment] Time to turn off the toxins: adjuvant suppression of group A streptococcus	Michael Marks, Shiranee Sriskandan	
2024-10-10	[Comment] Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis	Sylvie Pillet, Aymeric Cantais, Blandine Noailly, Fabienne Jospin, Franck Zekre, Oulfa Boussetta-Charfi, Sara Chenafi-Adham, Thomas Bourlet, Slim Fourati, Stéphane Paul	
2024-10-09	[Media Watch] Two pandemics, a shared lesson	Emma Starbuck	
2024-10-08	[Comment] Revisiting MERS-CoV vaccination in the SARS-CoV-2 era	Sarah A Batawi, Basem M Alraddadi	
2024-10-08	[Corrections] Correction to Lancet Infect Dis 2021; 21: 823–33		
2024-10-08	[Articles] Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial	Matthijs P Raadsen, Christine Dahlke, Anahita Fathi, Svenja Hardtke, Michael Klüver, Verena Krähling, Gesche K Gerresheim, Leonie Mayer, Anna Z Mykytyn, Leonie M Weskamm, Tamara Zoran, Eric C M van Gorp, Gerd Sutter, Stephan Becker, Bart L Haagmans, Maryl	
2024-10-08	[Articles] Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial	Yehuda Carmeli, José Miguel Cisneros, Mical Paul, George L Daikos, Minggui Wang, Julian Torre-Cisneros, George Singer, Ivan Titov, Illia Gumenchuk, Yongjie Zhao, Rosa-María Jiménez-Rodríguez, Lu Liang, Gang Chen, Oleksandr Pyptiuk, Firdevs Aksoy, Halley R	
2024-10-08	[Comment] REVISITing treatment of metallo-β-lactamases	Emily L Heil, Erin K McCreary	
2024-10-08	[Review] New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine	Andreas K Lindner, Veerle Lejon, Michael P Barrett, Lucille Blumberg, Salome A Bukachi, Rebecca J Chancey, Andrew Edielu, Lucas Matemba, Tihitina Mesha, Victor Mwanakasale, Christopher Pasi, Tapunda Phiri, Jorge Seixas, Elie A Akl, Katrin Probyn, Gemma Vi	
2024-10-08	[Correspondence] 12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Pad Chivukula, Ye Zhang, Judd L Walson	
2024-10-05	[Media Watch] Fail to prepare, prepare to fail	Jessica Pope	
2024-10-05	[Media Watch] A shared history	Claire Lenahan	
2024-10-04	[Media Watch] COVID-19 and sexual health rights in Africa	Aimee Ramgolam	
2024-10-04	[Newsdesk] Médecins Sans Frontières ceases activity in Russia	Ed Holt	
2024-10-01	[Comment] Heading in the direction of ending human deaths from dog-mediated rabies	Maria Cristina Schneider, Sofia Sciancalepore	
2024-10-01	[Articles] Estimates of the burden of human rabies deaths and animal bites in India, 2022–23: a community-based cross-sectional survey and probability decision-tree modelling study	Jeromie Wesley Vivian Thangaraj, Navaneeth S Krishna, Shanmugasundaram Devika, Suganya Egambaram, Sudha Rani Dhanapal, Siraj Ahmed Khan, Ashok Kumar Srivastava, Ayush Mishra, Basavaraj Shrinivasa, Devendra Gour, Major Madhukar, Nirmal Verma, Parul Sharma,	
2024-09-28	[Correspondence] Preparing for the rapid research response to the possible vertical transmission of Oropouche virus: lessons from a decade of congenital Zika research	Elizabeth B Brickley, Demócrito de Barros Miranda-Filho, Ricardo Arraes de Alencar Ximenes, MERG, ZBC-Consortium, and LIFE Zika Study members	
2024-09-27	[Personal View] Advancing the chemotherapy of tuberculous meningitis: a consensus view	Sean Wasserman, Joseph Donovan, Evelyne Kestelyn, James A Watson, Robert E Aarnoutse, James R Barnacle, David R Boulware, Felicia C Chow, Fiona V Cresswell, Angharad G Davis, Kelly E Dooley, Anthony A Figaji, Diana M Gibb, Julie Huynh, Darma Imran, Suzaan	
2024-09-26	[Correspondence] Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination	Christine Happle, Markus Hoffmann, Amy Kempf, Inga Nehlmeier, Metodi V Stankov, Noemi Calderon Hampel, Torsten Witte, Stefan Pöhlmann, Georg M N Behrens, Alexandra Dopfer-Jablonka	
2024-09-25	[Articles] Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial	Amparo L Figueroa, Dania Torres, Celia Reyes-Acuna, Paul Matherne, Anne Yeakey, Weiping Deng, Wenqin Xu, Yelena Sigal, Greer Chambers, Michelle Olsen, Bethany Girard, Jacqueline M Miller, Rituparna Das, Frances Priddy	
2024-09-25	[Comment] COVID-19 immunisation strategies for adolescents	Wei-Xiao Wang, Feng-Cai Zhu	
2024-09-24	[Review] The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access	Jonne Terstappen, Sarah F Hak, Anant Bhan, Debby Bogaert, Louis J Bont, Ursula J Buchholz, Andrew D Clark, Cheryl Cohen, Ron Dagan, Daniel R Feikin, Barney S Graham, Anuradha Gupta, Pradeep Haldar, Rose Jalang'o, Ruth A Karron, Leyla Kragten, You Li, Yvet	
2024-09-24	[Review] Optimising vaccine immunogenicity in ageing populations: key strategies	Guangzhen Jiang, Yushu Zou, Dongyu Zhao, Jingyou Yu	
2024-09-24	[Personal View] A pox on all our houses: a missing component in the global mpox response is equity	Eddy Jonas, Nesar Hamraz, Nathalie Marcadieu, Daphnee Salomon, Deogratias Niyizonkiza, Jennifer Furin, Jacklin Saint Fleur	
2024-09-21	[Comment] Difficulties in diagnosing tuberculosis infection in childhood	Anna Starshinova	
2024-09-21	[Media Watch] Globalisation and COVID-19	Matilda Lawson	
2024-09-21	[Corrections] Correction to Lancet Infect Dis 2024; published online Sept 10. https://doi.org/10.1016/S1473-3099(24)00585-1		
2024-09-21	[Articles] Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study	Laura Olbrich, Zoe Franckling-Smith, Leyla Larsson, Issa Sabi, Nyanda Elias Ntinginya, Celso Khosa, Denise Banze, Marriott Nliwasa, Elizabeth Lucy Corbett, Robina Semphere, Valsan Philip Verghese, Joy Sarojini Michael, Marilyn Mary Ninan, Elmar Saathoff,	
2024-09-21	[Correspondence] Financing infectious disease services in hospitals: a common public good	Joseph D Tucker	
2024-09-21	[Media Watch] Vaccine hesitancy in Scandinavia	Hollie Sherwood-Martin	
2024-09-20	[Articles] Mosquito-disseminated pyriproxyfen for mosquito-borne disease control in Belo Horizonte, Brazil: a pragmatic, before–after control–intervention paired-series trial	Fernando Abad-Franch, José Joaquín Carvajal-Cortés, Ana Carolina Lemos Rabelo, Eduardo Viana Vieira Gusmão, Samylla Suany de Souza Soares, Sérgio Luiz Bessa Luz	
2024-09-20	[Comment] Quantifying the effect of vector targeted interventions to control dengue	Henrik Salje	
2024-09-19	[Articles] Temporary adaptations to sexual behaviour during the mpox outbreak in 23 countries in Europe and the Americas: findings from a retrospective cross-sectional online survey	Mateo Prochazka, Pietro Vinti, Ana Hoxha, Andy Seale, Antons Mozalevskis, Rosamund Lewis, Ruben Mayorga Sagastume, Martha Scherzer, Leilia Dore, Meg Doherty	
2024-09-19	[Personal View] Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	Richard Kwizera, Alireza Abdolrasouli, Guillermo Garcia-Effron, David W Denning	
2024-09-19	[Comment] Mpox control strategies: using behaviour change to complement, not replace, vaccination	Marc C Shamier, Kai J Jonas	
2024-09-13	[Newsdesk] Polio vaccination campaign in Gaza	Talha Burki	
2024-09-12	[Articles] Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study	Timothy W Russell, Hermaleigh Townsley, Joel Hellewell, Joshua Gahir, Marianne Shawe-Taylor, David Greenwood, David Hodgson, Agnieszka Hobbs, Giulia Dowgier, Rebecca Penn, Theo Sanderson, Phoebe Stevenson-Leggett, James Bazire, Ruth Harvey, Ashley S Fowle	
2024-09-12	[Comment] Kinetics of neutralising antibodies against SARS-CoV-2 variants	Piero Poletti	
2024-09-11	[Comment] The worsening mpox outbreak in Africa: a call to action	Krutika Kuppalli, Jake Dunning, Inger Damon, Daniel Mukadi-Bamuleka, Placide Mbala, Dimie Ogoina	
2024-09-11	[Correspondence] ArboTracker: a multipathogen dashboard and data platform for arbovirus seroprevalence studies	Mairead G Whelan, Harriet Ware, Himanshu Ranka, Sean Kenny, Sabah Shaikh, Yannik Roell, Shaila Akter, Anabel Selemon, Emilie Toews, May Chu, Niklas Bobrovitz, Rahul K Arora, Thomas Jaenisch	
2024-09-11	[Correspondence] Mpox outbreak—tecovirimat resistance, management approaches, and challenges in HIV-endemic regions	Wyvine Ansima Bapolisi, Susanne Krasemann, Misaki Wayengera, Bruce Kirenga, Esto Bahizire, Espoir Bwenge Malembaka, Joseph Nelson Siewe Fodjo, Robert Colebunders, Patrick DMC Katoto	
2024-09-10	[Articles] Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021	GBD 2021 Upper Respiratory Infections Otitis Media Collaborators	
2024-09-10	[Comment] SARS-CoV-2 antivirals and post-COVID-19 condition	Ziyad Al-Aly	
2024-09-10	[Articles] Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial	Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, Najib M Rahman, Duncan B Richards, Gail Hayward, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Stavros Petrou, Kerenza Hood, Haroon Ahmed, Andrew Carson-Stevens, Jon	
2024-09-10	[Comment] Burden of upper respiratory infections and otitis media	Tal Marom	
2024-09-10	[Correspondence] Potential vertical transmission of Oropouche virus during the current outbreak	Athina Samara, Conrado Milani Coutinho, Philip Veal, Jane Osborne, Geraldo Duarte, Shamez Ladhani, Asma Khalil	
2024-09-07	[Newsdesk] Mpox emergency in Africa	Esther Nakkazi	
2024-09-06	[Comment] Next-generation influenza vaccines based on mRNA technology	Irina Isakova-Sivak, Larisa Rudenko	
2024-09-06	[Articles] Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50–75 years: a phase 1/2, open-label, randomised trial	Denise Hsu, Akila Jayaraman, Alicia Pucci, Riya Joshi, Kevin Mancini, Hui Ling Chen, Kindra Koslovsky, Xuezhou Mao, Angela Choi, Carole Henry, Jignesh Vakil, Daniel Stadlbauer, Patricia Jorquera, Guha Asthagiri Arunkumar, Nelia E Sanchez-Crespo, L Tyler W	